Publications
Found 8 results
Filters: Author is R. Tungtrongchitr [Clear All Filters]
“Exome sequencing in Thai patients with familial obesity”, vol. 15, p. -, 2016.
, “Exome sequencing in Thai patients with familial obesity”, vol. 15, p. -, 2016.
, “Exome sequencing in Thai patients with familial obesity”, vol. 15, p. -, 2016.
, “Association between rs155971 in the PCSK1 gene and the lipid profile of obese Thai children: a family-based study”, vol. 14, pp. 9136-9144, 2015.
, , “BDNF Val66Met polymorphism and serum concentrations of BDNF with smoking in Thai males”, vol. 12, pp. 4925-4933, 2013.
, “Association of HTTLPR and 5-HT2A T102C polymorphisms with smoking characteristics and anthropometric profiles of Thai males”, vol. 11, pp. 4360-4369, 2012.
, Abdolmaleky HM, Faraone SV, Glatt SJ and Tsuang MT (2004). Meta-analysis of association between the T102C polymorphism of the 5HT2a receptor gene and schizophrenia. Schizophr. Res. 67: 53-62.
http://dx.doi.org/10.1016/S0920-9964(03)00183-X
Barnes NM and Sharp T (1999). A review of central 5-HT receptors and their function. Neuropharmacology 38: 1083- 1152.
http://dx.doi.org/10.1016/S0028-3908(99)00010-6
Batra V, Patkar AA, Berrettini WH, Weinstein SP, et al. (2003). The genetic determinants of smoking. Chest 123: 1730- 1739.
http://dx.doi.org/10.1378/chest.123.5.1730
PMid:12740294
Chen K, Yang W, Grimsby J and Shih JC (1992). The human 5-HT2 receptor is encoded by a multiple intron-exon gene. Brain Res. Mol. Brain Res. 14: 20-26.
http://dx.doi.org/10.1016/0169-328X(92)90005-V
Chu SL, Xiao D, Wang C and Jing H (2009). Association between 5-hydroxytryptamine transporter gene-linked polymorphic region and smoking behavior in Chinese males. Chin. Med. J. 122: 1365-1368.
Coto E, Reguero JR, Alvarez V, Morales B, et al. (2003). 5-Hydroxytryptamine 5-HT2A receptor and 5-hydroxytryptamine transporter polymorphisms in acute myocardial infarction. Clin. Sci. 104: 241-245.
http://dx.doi.org/10.1042/CS20020246
PMid:12605580
Currie PJ and Coscina DV (1998). 5-Hydroxytryptaminergic receptor agonists: effects on neuropeptide Y potentiation of feeding and respiratory quotient. Brain Res. 803: 212-217.
http://dx.doi.org/10.1016/S0006-8993(98)00643-X
Degiampietro P, Peheim E, Drew D, Graf H, et al. (1987). Determination of thiocyanate in plasma and saliva without deproteinisation and its validation as a smoking parameter. J. Clin. Chem. Clin. Biochem. 25: 711-717.
PMid:3694128
do Prado-Lima PA, Chatkin JM, Taufer M, Oliveira G, et al. (2004). Polymorphism of 5HT2A serotonin receptor gene is implicated in smoking addiction. Am. J. Med. Genet. B Neuropsychiatr. Genet. 128B: 90-93.
http://dx.doi.org/10.1002/ajmg.b.30004
PMid:15211639
Ebdrup BH, Rasmussen H, Arnt J and Glenthoj B (2011). Serotonin 2A receptor antagonists for treatment of schizophrenia. Expert. Opin. Investig. Drugs 20: 1211-1223.
http://dx.doi.org/10.1517/13543784.2011.601738
PMid:21740279
Erritzoe D, Frokjaer VG, Haugbol S, Marner L, et al. (2009). Brain serotonin 2A receptor binding: relations to body mass index, tobacco and alcohol use. Neuroimage 46: 23-30.
http://dx.doi.org/10.1016/j.neuroimage.2009.01.050
PMid:19457377
Gerra G, Garofano L, Zaimovic A, Moi G, et al. (2005). Association of the serotonin transporter promoter polymorphism with smoking behavior among adolescents. Am. J. Med. Genet. B Neuropsychiatr. Genet. 135B: 73-78.
http://dx.doi.org/10.1002/ajmg.b.30173
PMid:15806583
Greenberg BD, Tolliver TJ, Huang SJ, Li Q, et al. (1999). Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. Am. J. Med. Genet. 88: 83-87.
http://dx.doi.org/10.1002/(SICI)1096-8628(19990205)88:1<83::AID-AJMG15>3.0.CO;2-0
Heils A, Teufel A, Petri S, Stober G, et al. (1996). Allelic variation of human serotonin transporter gene expression. J. Neurochem. 66: 2621-2624.
http://dx.doi.org/10.1046/j.1471-4159.1996.66062621.x
PMid:8632190
Heils A, Mossner R and Lesch KP (1997). The human serotonin transporter gene polymorphism--basic research and clinical implications. J. Neural Transm. 104: 1005-1014.
http://dx.doi.org/10.1007/BF01273314
PMid:9503253
Huang S, Cook DG, Hinks LJ, Chen XH, et al. (2005). CYP2A6, MAOA, DBH, DRD4, and 5HT2A genotypes, smoking behaviour and cotinine levels in 1518 UK adolescents. Pharmacogenet. Genomics 15: 839-850.
http://dx.doi.org/10.1097/01213011-200512000-00002
PMid:16272956
Hwu HG and Chen CH (2000). Association of 5HT2A receptor gene polymorphism and alcohol abuse with behavior problems. Am. J. Med. Genet. 96: 797-800.
http://dx.doi.org/10.1002/1096-8628(20001204)96:6<797::AID-AJMG20>3.0.CO;2-K
Iordanidou M, Tavridou A, Petridis I, Kyroglou S, et al. (2010). Association of polymorphisms of the serotonergic system with smoking initiation in Caucasians. Drug Alcohol Depend. 108: 70-76.
http://dx.doi.org/10.1016/j.drugalcdep.2009.11.015
PMid:20060656
Ishikawa H, Ohtsuki T, Ishiguro H, Yamakawa-Kobayashi K, et al. (1999). Association between serotonin transporter gene polymorphism and smoking among Japanese males. Cancer Epidemiol. Biomarkers Prev. 8: 831-833.
PMid:10498403
Kato M, Zanardi R, Rossini D, De Ronchi D, et al. (2009). 5-HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients. Psychiatry Res. 167: 97-105.
http://dx.doi.org/10.1016/j.psychres.2007.12.012
PMid:19361869
Keltikangas-Jarvinen L and Salo J (2009). Dopamine and serotonin systems modify environmental effects on human behavior: a review. Scand. J. Psychol. 50: 574-582.
http://dx.doi.org/10.1111/j.1467-9450.2009.00785.x
PMid:19930256
Lane HY, Liu YC, Huang CL, Chang YC, et al. (2006). Risperidone-related weight gain: genetic and nongenetic predictors. J. Clin. Psychopharmacol. 26: 128-134.
http://dx.doi.org/10.1097/01.jcp.0000203196.65710.2b
PMid:16633140
Lerman C, Shields PG, Audrain J, Main D, et al. (1998). The role of the serotonin transporter gene in cigarette smoking. Cancer Epidemiol. Biomarkers Prev. 7: 253-255.
PMid:9521442
Lerman C, Caporaso NE, Audrain J, Main D, et al. (2000). Interacting effects of the serotonin transporter gene and neuroticism in smoking practices and nicotine dependence. Mol. Psychiatry 5: 189-192.
http://dx.doi.org/10.1038/sj.mp.4000672
PMid:10822347
Lesch KP, Bengel D, Heils A, Sabol SZ, et al. (1996). Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274: 1527-1531.
http://dx.doi.org/10.1126/science.274.5292.1527
PMid:8929413
Li MD, Cheng R, Ma JZ and Swan GE (2003). A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adult twins. Addiction 98: 23-31.
http://dx.doi.org/10.1046/j.1360-0443.2003.00295.x
PMid:12492752
Mihailescu S, Palomero-Rivero M, Meade-Huerta P, Maza-Flores A, et al. (1998). Effects of nicotine and mecamylamine on rat dorsal raphe neurons. Eur. J. Pharmacol. 360: 31-36.
http://dx.doi.org/10.1016/S0014-2999(98)00658-X
Munafo MR, Johnstone EC, Wileyto EP, Shields PG, et al. (2006). Lack of association of 5-HTTLPR genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiol. Biomarkers Prev. 15: 398-400.
http://dx.doi.org/10.1158/1055-9965.EPI-05-0648
PMid:16492936
Murphy DL, Lerner A, Rudnick G and Lesch KP (2004). Serotonin transporter: gene, genetic disorders, and pharmacogenetics. Mol. Interv. 4: 109-123.
http://dx.doi.org/10.1124/mi.4.2.8
PMid:15087484
Polesskaya OO and Sokolov BP (2002). Differential expression of the "C" and "T" alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics. J. Neurosci. Res. 67: 812-822.
http://dx.doi.org/10.1002/jnr.10173
PMid:11891796
Polina ER, Contini V, Hutz MH and Bau CH (2009). The serotonin 2A receptor gene in alcohol dependence and tobacco smoking. Drug Alcohol Depend. 101: 128-131.
http://dx.doi.org/10.1016/j.drugalcdep.2008.11.001
PMid:19111403
Rosmond R, Bouchard C and Björntorp P (2002). 5-HT2A receptor gene promoter polymorphism in relation to abdominal obesity and cortisol. Obes. Res. 10: 585-589.
http://dx.doi.org/10.1038/oby.2002.79
PMid:12105278
Terayama H, Itoh M, Fukunishi I and Iwahashi K (2004). The serotonin-2A receptor polymorphism and smoking behavior in Japan. Psychiatr. Genet. 14: 195-197.
http://dx.doi.org/10.1097/00041444-200412000-00005
PMid:15564892
Turecki G, Briere R, Dewar K, Antonetti T, et al. (1999). Prediction of level of serotonin 2A receptor binding by serotonin receptor 2A genetic variation in postmortem brain samples from subjects who did or did not commit suicide. Am. J. Psychiatry 156: 1456-1458.
PMid:10484964
Tyndale RF (2003). Genetics of alcohol and tobacco use in humans. Ann. Med. 35: 94-121.
http://dx.doi.org/10.1080/07853890310010014
PMid:12795339
Vink JM, Smit AB, de Geus EJ, Sullivan P, et al. (2009). Genome-wide association study of smoking initiation and current smoking. Am. J. Hum. Genet. 84: 367-379.
http://dx.doi.org/10.1016/j.ajhg.2009.02.001
PMid:19268276 PMCid:2667987
White MJ, Young RM, Morris CP and Lawford BR (2011). Cigarette smoking in young adults: the influence of the HTR2A T102C polymorphism and punishment sensitivity. Drug Alcohol Depend. 114: 140-146.
PMid:21035274
Yonan AL, Palmer AA and Gilliam TC (2006). Hardy-Weinberg disequilibrium identified genotyping error of the serotonin transporter (SLC6A4) promoter polymorphism. Psychiatr. Genet. 16: 31-34.
http://dx.doi.org/10.1097/01.ypg.0000174393.79883.05
PMid:16395127
Zaniewska M, McCreary AC, Wydra K and Filip M (2010). Effects of serotonin (5-HT)2 receptor ligands on depression-like behavior during nicotine withdrawal. Neuropharmacology 58: 1140-1146.
http://dx.doi.org/10.1016/j.neuropharm.2010.02.006
PMid:20153341
Zeidler R, Albermann K and Lang S (2007). Nicotine and apoptosis. Apoptosis 12: 1927-1943.
http://dx.doi.org/10.1007/s10495-007-0102-8
PMid:17846896
“Association of T869C gene polymorphism of transforming growth factor-β1 with low protein levels and anthropometric indices in osteopenia/osteoporosis postmenopausal Thai women”, vol. 11, pp. 87-99, 2012.
, Awad MR, El-Gamel A, Hasleton P, Turner DM, et al. (1998). Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 66: 1014-1020.
http://dx.doi.org/10.1097/00007890-199810270-00009
PMid:9808485
Barrera G, Bunout D, Gattas V, de la Maza MP, et al. (2004). A high body mass index protects against femoral neck osteoporosis in healthy elderly subjects. Nutrition 20: 769-771.
http://dx.doi.org/10.1016/j.nut.2004.05.014
PMid:15325685
Derynck R, Jarrett JA, Chen EY, Eaton DH, et al. (1985). Human transforming growth factor-b complementary DNA sequence and expression in normal and transformed cells. Nature 316: 701-705.
http://dx.doi.org/10.1038/316701a0
PMid:3861940
Derynck R, Rhee L, Chen EY and Van Tilburg A (1987). Intron-exon structure of the human transforming growth factor-b precursor gene. Nucleic Acids Res. 15: 3188-3189.
http://dx.doi.org/10.1093/nar/15.7.3188
PMid:3470709 PMCid:340929
Gazit D, Zilberman Y, Ebner R and Kahn A (1998). Bone loss (osteopenia) in old male mice results from diminished activity and availability of TGF-beta. J. Cell Biochem. 70: 478-488.
http://dx.doi.org/10.1002/(SICI)1097-4644(19980915)70:4<478::AID-JCB5>3.0.CO;2-G
Grainger DJ, Heathcote K, Chiano M, Snieder H, et al. (1999). Genetic control of the circulating concentration of transforming growth factor type beta1. Hum. Mol. Genet. 8: 93-97.
http://dx.doi.org/10.1093/hmg/8.1.93
PMid:9887336
Hinke V, Seck T, Clanget C, Scheidt-Nave C, et al. (2001). Association of transforming growth factor-beta1 (TGFbeta1) T29→C gene polymorphism with bone mineral density (BMD), changes in BMD, and serum concentrations of TGF-beta1 in a population-based sample of postmenopausal German women. Calcif. Tissue Int. 69: 315-320.
http://dx.doi.org/10.1007/s002230020024
PMid:11800227
Huang QY and Kung AW (2006). Genetics of osteoporosis. Mol. Genet. Metab. 88: 295-306.
http://dx.doi.org/10.1016/j.ymgme.2006.04.009
PMid:16762578
Hunter DJ and Sambrook PN (2000). Bone loss: Epidemiology of bone loss. Arthritis Res. 2: 441-445.
http://dx.doi.org/10.1186/ar125
PMid:11094456 PMCid:128872
Kanaan RA and Kanaan LA (2006). Transforming growth factor-b1, bone connection. Med. Sci. Monit. 12: RA164- RA169.
PMid:16865078
Langdahl BL, Knudsen JY, Jensen HK, Gregersen N, et al. (1997). A sequence variation: 713-8delC in the transforming growth factor-beta 1 gene has higher prevalence in osteoporotic women than in normal women and is associated with very low bone mass in osteoporotic women and increased bone turnover in both osteoporotic and normal women. Bone 20: 289-294.
http://dx.doi.org/10.1016/S8756-3282(96)00363-8
Langdahl BL, Carstens M, Stenkjaer L and Eriksen EF (2003). Polymorphisms in the transforming growth factor beta 1 gene and osteoporosis. Bone 32: 297-310.
http://dx.doi.org/10.1016/S8756-3282(02)00971-7
Lau HHL, Ho AYY, Luk KDK and Kung AWC (2004). Transforming growth factor-b1 gene polymorphisms and bone turnover, bone mineral density and fracture riskin Southern Chinese women. Calcif. Tissue Int. 74: 516-521.
http://dx.doi.org/10.1007/s00223-004-0163-4
PMid:15354859
Looker AC, Orwoll ES, Johnston CC Jr, Lindsay RL, et al. (1997). Prevalence of low femoral bone density in older U.S. adults from NHANES III. J. Bone Miner. Res. 12: 1761-1768.
http://dx.doi.org/10.1359/jbmr.1997.12.11.1761
PMid:9383679
Pongchaiyakul C, Songpattanasilp T and Taechakraichana N (2008). Burden of osteoporosis in Thailand. J. Med. Assoc. Thai. 91: 261-267.
PMid:18389994
Ryan TA, Brian LB and Ryan BF (1985). Minitab Student Handbook. 2nd edn. PWS Kent Publishing Company, Boston.
Shu XO, Gao YT, Cai Q, Pierce L, et al. (2004). Genetic polymorphisms in the TGF-b1 gene and breast cancer survival: a report from the Shanghai breast cancer study. Cancer Res. 64: 836-839.
http://dx.doi.org/10.1158/0008-5472.CAN-03-3492
PMid:14871809
Williams FM and Spector TD (2006). Recent advances in the genetics of osteoporosis. J. Musculoskelet. Neuronal. Interact. 6: 27-35.
PMid:16675887
Wood NA, Thomson SC, Smith RM and Bidwell JL (2000). Identification of human TGF-b1 signal (leader) sequence polymorphisms by PCR-RFLP. J. Immunol. Methods 234: 117-122.
http://dx.doi.org/10.1016/S0022-1759(99)00127-1
World Health Organization (2003). Prevention and Management of Osteoporosis. WHO Technical Report Series 921, Geneva.
Yamada Y, Miyauchi A, Goto J, Takagi Y, et al. (1998). Association of a polymorphism of the transforming growth factor-b1 gene with genetic susceptibility to osteoporosis in postmenopausal Japanese women. J. Bone Miner. Res. 13: 1569-1575.
http://dx.doi.org/10.1359/jbmr.1998.13.10.1569
PMid:9783545
Yamada Y, Miyauchi A, Takagi Y, Tanaka M, et al. (2001). Association of the C-509→T polymorphism, alone of in combination with the T869→C polymorphism, of the transforming growth factor-b1 gene with bone mineral density and genetic susceptibility to osteoporosis in Japanese women. J. Mol. Med. 79: 149-156.
http://dx.doi.org/10.1007/s001090100190
PMid:11357939
Yoshiji Y (2000). Association of a Leu10→Pro polymorphism of the transforming growth factor-beta1 with genetic susceptibility to osteoporosis and spinal osteoarthritis. Mech. Ageing Dev. 116: 113-123.
http://dx.doi.org/10.1016/S0047-6374(00)00131-7
Ziv E, Kahn A, Cauley J, Morin P, et al. (2003). No association between the TGF-b1 Leu10Pro polymorphism and osteoporosis among white women in the United States. Am. J. Med. 114: 227-231.
http://dx.doi.org/10.1016/S0002-9343(02)01393-1